+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Atrial Natriuretic Peptide Increases Urodilatin in the Circulation

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background: Urodilatin is a 32-amino-acid (AA) peptide formed in the kidney. Methods: High-performance gel permeation chromatography and high-pressure liquid chromatography evaluation of plasma followed by sensitive urodilatin and atrial natriuretic peptide (ANP) assays revealed that urodilatin does circulate distinctly from ANP. Results: Urodilatin circulates at very low levels (i.e 9–12 pg/ml). Infusion of ANP increased the circulating concentration of urodilatin 135-fold (p < 0.001), suggesting that some of the effects of ANP may be mediated by urodilatin while long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide did not affect urodilatin in healthy humans (n = 30). Only ANP decreased the renal clearance of urodilatin (60–75%, p < 0.01). Urodilatin was metabolized into peptides smaller than 5 AAs as well as excreted intact into urine. Conclusion: Urodilatin circulates and is increased by ANP in humans.

          Related collections

          Most cited references 2

          • Record: found
          • Abstract: not found
          • Article: not found

          Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites

            • Record: found
            • Abstract: not found
            • Article: not found

            Specific binding sites for prohormone atrial natriuretic peptides 1–30, 31–67 and 99–126


              Author and article information

              Am J Nephrol
              American Journal of Nephrology
              S. Karger AG
              June 1998
              06 May 1998
              : 18
              : 3
              : 204-213
              Departments of Medicine, Pharmacy, Physiology and Biophysics, James A. Haley Veterans Hospital, and University of South Florida Health Sciences Center, Tampa, Fla., USA
              13338 Am J Nephrol 1998;18:204–213
              © 1998 S. Karger AG, Basel

              Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

              Page count
              Figures: 6, Tables: 1, References: 38, Pages: 10
              Self URI (application/pdf):
              Clinical Study


              Comment on this article